Lundbeck’s Lu AF35700 misses schizophrenia endpoint

The first Phase III trial from H. Lundbeck A/S (CSE:LUN) to read out since CEO Deborah Dunsire took the helm last month has missed its primary endpoint. Lundbeck reported that Lu AF35700 missed the primary endpoint in the Phase III DAYBREAK trial for treatment-resistant schizophrenia.

Dunsire become president and CEO on Sept. 1, filling a position that became vacant when Kåre Schultz resigned in September 2017. CFO Anders Götzsche had been serving as interim CEO since November 2017...